Abstract Number: 1554 • ACR Convergence 2022
Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis
Background/Purpose: 18FDG-PET imaging can be used to directly assess vascular inflammation; however, limited access to this technology has restricted widespread adoption of this modality in…Abstract Number: 2240 • ACR Convergence 2022
Autoimmunity Against Melanoma Differentiation-Associated Protein 5 Advances Acute Lung Injury to Interstitial Lung Disease in Mice
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) is characterized by amyopathic DM with interstitial lung disease (ILD). Patients with anti-MDA5 antibody-associated DM sometimes…Abstract Number: 0626 • ACR Convergence 2022
Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
Background/Purpose: Proprotein convertase subtilisin/Kexin type-9 (PCSK9) is the most recognized serine protease for its pathological role in cardiovascular diseases, however, its role in inflammatory diseases,…Abstract Number: 1559 • ACR Convergence 2022
Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines
Background/Purpose: Apremilast, the small-molecule phosphodiesterase -4 inhibitor, was approved for the treatment of recurrent oral ulcers associated with Behcet's disease (BD) in Japan from September…Abstract Number: 2264 • ACR Convergence 2022
Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome
Background/Purpose: Heterozygous gain-of-function mutations in STAT1 promote a complex disorder of immune dysregulation including chronic mucocutaneous candidiasis (CMC) and systemic autoimmunity. However, given widespread expression…Abstract Number: 0636 • ACR Convergence 2022
Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment
Background/Purpose: There is a pressing need to identify novel therapeutic approaches and noninvasive biomarkers in lupus nephritis (LN). In this study, we quantified serum soluble…Abstract Number: 1560 • ACR Convergence 2022
Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease
Background/Purpose: Behçet disease (BD) is an inflammatory chronic disease characterized by alternation of active and inactive phases. Steroids, Colchine, Azathioprine (Aza) and interferon α are…Abstract Number: 0039 • ACR Convergence 2022
Type I and Type II Interferon and NF-κB-Response Gene Scores and Serum Cytokine Levels in Patients with Various Systemic Autoinflammatory Diseases
Background/Purpose: Patients with systemic autoinflammatory diseases (SAIDs) present with chronic and acute elevations of proinflammatory serum cytokine and chemokine levels during exacerbations of disease flares.…Abstract Number: 0639 • ACR Convergence 2022
Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity
Background/Purpose: High titer anti-Ro+ mothers of children with neonatal lupus (NL), often completely asymptomatic, offer a unique opportunity to uncover insights into permissive and protective…Abstract Number: 1624 • ACR Convergence 2022
Blocking IL-1, IL-33 and IL-36 Signaling with the Anti-IL1RAP Antibody mCAN10 Ameliorates Inflammation and Fibrosis in Preclinical Models of Systemic Sclerosis
Background/Purpose: The IL-1 receptor accessory protein (IL1RAP) is a co-receptor required for signaling through the IL-1, IL-33, and IL-36 receptors. IL1RAP-dependent signaling has been implicated…Abstract Number: 0266 • ACR Convergence 2022
Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression
Background/Purpose: Autoantibody responses rise years before onset of inflammatory arthritis (IA) and are stable during transitioning from clinically suspect arthralgia (CSA) to IA (1). Cytokine…Abstract Number: 0652 • ACR Convergence 2022
Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway
Background/Purpose: Although type 1 interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM) [1] as typically evidenced…Abstract Number: 1686 • ACR Convergence 2022
Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts
Background/Purpose: Post-translational modifications with malondialdehyde-acetaldehyde (MAA) alter protein structure and function, inducing pro-inflammatory and pro-fibrotic responses characteristic of rheumatoid arthritis (RA). Matrix-gla protein (MGP) chelates…Abstract Number: 0499 • ACR Convergence 2022
Drivers of Heterogeneity in Synovial Fibroblasts in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplasia of both the synovial lining, which forms the synovial fluid interface, as well as the synovial sublining,…Abstract Number: 0666 • ACR Convergence 2022
HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 38
- Next Page »